Genes, not race, determine donor kidney survival

A new study by researchers at Wake Forest Baptist Medical Center sheds light on what causes certain kidneys to do better than others after being transplanted, providing doctors with an easy way to screen for donor kidneys that have the best chance of survival.

"It's been long observed that kidneys taken from some black donors just don't last as long as those taken from non-black donors, and the reason for that has not been known," said Barry I. Freedman, M.D., John H. Felts III Professor and senior investigator. "This study reveals that the of the has a marked affect on graft survival after transplantation. We now know that these organs aren't failing because they came from black donors, but rather because they came from individuals with two copies of a specific recessive gene."

The study appears in the May issue of the .

Freedman and co-researchers at Wake Forest Baptist examined 12 years' worth of dating back to 1998, looking for all patients who received a transplant from a black deceased donor whose had been recorded. The search yielded 106 black donors – from whom one or both kidneys were transplanted – for a total of 136 donated kidneys.

The researchers identified that kidneys from donors who had specific coding changes in a gene called apolipoprotein L1 (APOL1) did not last as long after transplant as those from donors without these changes. These coding changes in the APOL1 gene that affect function are found in about 10 to 12 percent of black individuals. Recent studies, led by Freedman and his colleagues, have shown that these genetic changes are associated with an increased risk of kidney disease, which prompted researchers to investigate the role of these changes in transplant success.

"In looking at the records and follow-up of the recipients of these organs, we accounted for all the usual factors that are known to contribute to more rapid loss of kidney function after transplant," said Freedman, chief of the section on nephrology. "What we found was that the kidney disease-causing risk variants in APOL1 were the strongest predictor of graft loss after transplant. The effect of having two copies of this gene was stronger than the impact of genetic matching between donor and recipient, the amount of time the organ was out of the body, and the antibody levels. APOL1 dwarfed all these other factors known to affect survival."

If the finding is confirmed by other researchers, it has the potential to dramatically improve outcomes for both the individuals undergoing kidney transplantation and those considering kidney donation, Freedman said. It could revolutionize donor selection criteria, allowing transplant physicians the ability to identify kidneys that are likely to function for shorter periods of time. In addition, this screening tool has the potential to help doctors protect potential donors who may be at risk of developing kidney disease down the road.

"It is exciting to see that research done at Wake Forest Baptist could impact kidney transplantation throughout the world," Freedman said. "We have shown for the first time that genetic risk variants in kidney donors are associated with markedly different outcomes after . This finding could dramatically change the way we practice."

Provided by Wake Forest Baptist Medical Center

5 /5 (1 vote)

Related Stories

Most kidney transplant candidates will accept risk of infection

Mar 25, 2010

Most kidney transplant candidates are willing to receive a kidney from a donor at increased risk of viral infection, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN ...

Increasing the number of kidney transplants

Aug 20, 2009

In most transplant centers, the kidneys of very young deceased donors are transplanted together into one patient. According to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (C ...

Recommended for you

New approach to particle therapy dosimetry

7 hours ago

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.